Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to report the treatment effect and safety of combined
intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a
reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to
pathologic myopia.
Phase:
Phase 1
Details
Lead Sponsor:
Second University of Naples University of Campania "Luigi Vanvitelli"